Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.
The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids. In addition, Virios is advancing VTI-105, which is being evaluated for its potential to promote wound healing in patients with diabetic foot ulcers. These programs reflect Virios’s broader strategy of addressing both dermatological and systemic fibrotic indications through targeted inhibition of pro-fibrotic signaling cascades.
Headquartered in St. Louis, Missouri, Virios operates research and development activities in the United States. Since going public on the Nasdaq exchange under the ticker VIRI, the company has collaborated with academic institutions and contract research organizations to support its preclinical and clinical studies. Virios’s leadership team is spearheaded by Chief Executive Officer Sumita Roy, Ph.D., whose experience in drug discovery and translational research guides the company’s scientific and strategic direction.
As a specialty biopharma enterprise, Virios Therapeutics is committed to advancing innovative therapies from early-stage research through regulatory approval. By focusing on diseases characterized by excessive scarring and impaired healing, the company seeks to bring novel treatment modalities to patients and create long-term value for stakeholders.
AI Generated. May Contain Errors.
